1. Home
  2. ADVB vs RNTX Comparison

ADVB vs RNTX Comparison

Compare ADVB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVB
  • RNTX
  • Stock Information
  • Founded
  • ADVB 2014
  • RNTX 2001
  • Country
  • ADVB United States
  • RNTX United States
  • Employees
  • ADVB N/A
  • RNTX N/A
  • Industry
  • ADVB Medical Specialities
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVB Health Care
  • RNTX Health Care
  • Exchange
  • ADVB Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • ADVB 36.1M
  • RNTX 40.3M
  • IPO Year
  • ADVB 2025
  • RNTX N/A
  • Fundamental
  • Price
  • ADVB $1.03
  • RNTX $1.95
  • Analyst Decision
  • ADVB
  • RNTX
  • Analyst Count
  • ADVB 0
  • RNTX 0
  • Target Price
  • ADVB N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • ADVB 197.6K
  • RNTX 52.1K
  • Earning Date
  • ADVB 01-01-0001
  • RNTX 05-15-2025
  • Dividend Yield
  • ADVB N/A
  • RNTX N/A
  • EPS Growth
  • ADVB N/A
  • RNTX N/A
  • EPS
  • ADVB N/A
  • RNTX N/A
  • Revenue
  • ADVB N/A
  • RNTX N/A
  • Revenue This Year
  • ADVB N/A
  • RNTX N/A
  • Revenue Next Year
  • ADVB N/A
  • RNTX N/A
  • P/E Ratio
  • ADVB N/A
  • RNTX N/A
  • Revenue Growth
  • ADVB N/A
  • RNTX N/A
  • 52 Week Low
  • ADVB $0.86
  • RNTX $1.35
  • 52 Week High
  • ADVB $4.10
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • ADVB N/A
  • RNTX N/A
  • Support Level
  • ADVB N/A
  • RNTX N/A
  • Resistance Level
  • ADVB N/A
  • RNTX N/A
  • Average True Range (ATR)
  • ADVB 0.00
  • RNTX 0.00
  • MACD
  • ADVB 0.00
  • RNTX 0.00
  • Stochastic Oscillator
  • ADVB 0.00
  • RNTX 0.00

About ADVB Advanced Biomed Inc. Common Stock

Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: